Document is current
Any future updates will be listed below
-
Authors
Jacobs, Cale A.
Olsen, Zachary M.
Marchand, Lucas S.
Kraus, Virginia B.
Anderson, Donald D.
Haller, Justin
-
Funding
Funding for this research was provided by:
Arthritis Foundation
- License Information
-
More Information
Article History
Received: 20 September 2022
Accepted: 17 October 2022
First Online: 29 October 2022
Declarations
:
: There were no direct conflicts of interest related to the current work. Portions of this project were funded by a grant through the Arthritis Foundation’s Osteoarthritis-Clinical Trial Network. Potential conflicts not directly related to the current work include: Cale A. Jacobs (Research support: Flexion Therapeutics, Smith & Nephew), Virginia B. Kraus (Paid consultant: Flexion Therapeutics, Gilead, Novartis, Paradigm Biopharma, Unity Biotechnology, Research support: Zimmer), Donald D. Anderson (Stock or Stock Options: Iowa Simulation Solutions), and Justin Haller (Paid Consultant: NewClip Technics, Osteocentric, Stryker).
: There were no direct conflicts of interest related to the current work. Portions of this project were funded by a grant through the Arthritis Foundation’s Osteoarthritis-Clinical Trial Network. Potential conflicts not directly related to the current work include: Cale A. Jacobs (Research support: Flexion Therapeutics, Smith & Nephew), Virginia B. Kraus (Paid consultant: Flexion Therapeutics, Gilead, Novartis, Paradigm Biopharma, Unity Biotechnology, Research support: Zimmer), Donald D. Anderson (Stock or Stock Options: Iowa Simulation Solutions), and Justin Haller (Paid Consultant: NewClip Technics, Osteocentric, Stryker).
: This study was approved by the University of Utah IRB.
: All patients provided written informed consent prior to participating in this study.
